Medtronic (MDT) Financials: History & Chart

Medtronic plc (MDT)MDTMedtronic plc

About Medtronic plc

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

Galway, GA

95,000 employees

www.medtronic.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Geoffrey Straub Martha

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Apr 2026	Quarter ended Jan 2026	Quarter ended Oct 2025	Quarter ended Jul 2025	Quarter ended Apr 2025	Quarter ended Apr 2025	Quarter ended Jan 2025	Quarter ended Oct 2024
Revenue	36.36B	9.81B	9.02B	8.96B	8.58B	8.93B	N/A	8.29B	8.40B
Cost of Goods Sold	12.72B	2.37B	3.17B	3.56B	3.63B	3.15B	N/A	2.78B	2.95B
Gross Profit	23.64B	7.44B	5.85B	5.41B	4.95B	5.78B	N/A	5.51B	5.46B
Gross Profit Margin	65.0%	75.9%	64.9%	60.3%	57.7%	64.7%	N/A	66.5%	64.9%
Total Operating Expenses	17.18B	5.88B	4.08B	3.72B	3.50B	4.34B	N/A	3.87B	3.86B
Research & Development	2.87B	671.00M	722.00M	754.00M	726.00M	684.00M	N/A	675.00M	697.00M
Selling, General & Administrative	11.78B	3.06B	2.96B	2.97B	2.81B	2.72B	N/A	2.72B	2.76B
Operating Income (EBIT)	6.47B	1.56B	1.77B	1.69B	1.45B	1.44B	N/A	1.65B	1.59B
Operating Margin	17.8%	15.9%	19.7%	18.8%	16.8%	16.1%	N/A	19.9%	19.0%
Income Before Tax (EBT)	6.14B	1.83B	1.40B	1.60B	1.30B	1.26B	N/A	1.54B	1.56B
Interest Income	N/A	-154.00M	121.00M	N/A	33.00M	N/A	N/A	N/A	N/A
Interest Expense	715.00M	177.00M	181.00M	181.00M	176.00M	174.00M	N/A	179.00M	209.00M
Other Income/Expense	-331.00M	270.00M	-369.00M	-89.00M	-143.00M	-175.00M	N/A	-106.00M	-36.00M
Net Income	4.80B	1.24B	1.14B	1.37B	1.04B	1.06B	N/A	1.29B	1.27B
Income Tax Expense	1.30B	575.00M	254.00M	215.00M	255.00M	199.00M	N/A	237.00M	281.00M
Net Profit Margin	13.2%	12.7%	12.7%	15.3%	12.1%	11.8%	N/A	15.6%	15.1%
EBITDA	9.33B	2.19B	2.68B	2.27B	2.19B	2.28B	N/A	2.33B	2.27B
EBITDA Margin	25.7%	22.3%	29.7%	25.4%	25.6%	25.5%	N/A	28.1%	27.0%
Depreciation & Amortization	2.87B	625.00M	905.00M	589.00M	748.00M	840.00M	N/A	684.00M	675.00M
EPS Basic	3.75	0.98	0.89	1.07	0.81	0.82	N/A	1.01	0.99
EPS Diluted	3.73	0.96	0.89	1.07	0.81	0.82	N/A	1.01	0.99
Shares Outstanding	1.28B	1.28B	1.28B	1.28B	1.28B	1.28B	N/A	1.28B	1.28B
Diluted Shares Outstanding	1.29B	1.29B	1.29B	1.29B	1.29B	1.29B	N/A	1.29B	1.29B

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	04/24/2026	04/30/2025	04/25/2025	04/30/2024	04/26/2024	04/30/2023	04/28/2023	04/30/2022
Revenue	36.36B	33.54B	N/A	32.36B	N/A	31.23B	N/A	31.69B
Cost of Goods Sold	12.72B	11.63B	N/A	11.22B	N/A	10.72B	N/A	10.14B
Gross Profit	23.64B	21.91B	N/A	21.15B	N/A	20.51B	N/A	21.54B
Gross Profit Margin	65.0%	65.3%	N/A	65.3%	N/A	65.7%	N/A	68.0%
Total Operating Expenses	17.18B	15.95B	N/A	16.00B	N/A	15.02B	N/A	15.79B
Research & Development	2.87B	2.73B	N/A	2.73B	N/A	2.70B	N/A	2.75B
Selling, General & Administrative	11.78B	10.85B	N/A	10.74B	N/A	10.41B	N/A	10.29B
Operating Income (EBIT)	6.47B	5.96B	N/A	5.14B	N/A	5.49B	N/A	5.75B
Operating Margin	17.8%	17.8%	N/A	15.9%	N/A	17.6%	N/A	18.2%
Income Before Tax (EBT)	6.14B	5.63B	N/A	4.84B	N/A	5.36B	N/A	5.52B
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	715.00M	729.00M	N/A	719.00M	N/A	636.00M	N/A	553.00M
Other Income/Expense	-331.00M	-327.00M	N/A	-307.00M	N/A	-121.00M	N/A	-235.00M
Net Income	4.80B	4.66B	N/A	3.68B	N/A	3.76B	N/A	5.04B
Income Tax Expense	1.30B	936.00M	N/A	1.13B	N/A	1.58B	N/A	456.00M
Net Profit Margin	13.2%	13.9%	N/A	11.4%	N/A	12.0%	N/A	15.9%
EBITDA	9.43B	8.82B	N/A	7.79B	N/A	8.18B	N/A	8.46B
EBITDA Margin	25.9%	26.3%	N/A	24.1%	N/A	26.2%	N/A	26.7%
Depreciation & Amortization	2.96B	2.86B	N/A	2.65B	N/A	2.70B	N/A	2.71B
EPS Basic	3.75	3.63	N/A	2.77	N/A	2.83	N/A	3.75
EPS Diluted	3.73	3.61	N/A	2.76	N/A	2.82	N/A	3.73
Shares Outstanding	1.28B	1.29B	N/A	1.33B	N/A	1.33B	N/A	1.34B
Diluted Shares Outstanding	1.29B	1.29B	N/A	1.33B	N/A	1.33B	N/A	1.35B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.